Tanaproget

Tanaproget
Clinical data
ATC code	none;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile;
CAS Number	304853-42-7;
PubChem CID	4369524;
DrugBank	DB04787;
ChemSpider	3572060;
UNII	W9F9H8GXWR;
CompTox Dashboard (EPA)	DTXSID00184556 ;
ECHA InfoCard	100.217.016
Chemical and physical data
Formula	C16H15N3OS
Molar mass	297.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1(C2=C(C=CC(=C2)C3=CC=C(N3C)C#N)NC(=S)O1)C;
	InChI InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21); Key:PYVFWTPEBMRKSR-UHFFFAOYSA-N;

Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational nonsteroidal progestin.^[1] It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR).^[1] Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison.^[1] As of December 2010,^[2] it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.^[3]^[4]

An analog of tanaproget, 4-fluoropropyltanaproget (¹⁸F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.^[5]

References